JP2006314713A - Capsule endoscope - Google Patents

Abstract

<P>PROBLEM TO BE SOLVED: To provide a capsule endoscope which enables effective treatment and examination at a desired site in vivo along with excellent contamination preventing performance for bloods, proteins and the like by arranging effects of medicines at least on a part of surface and also facilitates the control of attitudes, motions and positions. <P>SOLUTION: The endoscope has effects of medicines at least on a part of surface of the capsule endoscope. Preferably, one mode is that the effects of medicines should be at least one kind selected from among a medicine for peripheral nerves, a medicine for central nerves, a hormone drug, an autacoid, a medicine for circulatory system, a medicine for respiratory system, a medicine for digestive system, a medicine for urogenital system, a medicine acting on skin, a vitamin drug, a chemical treatment drug, a disinfectant, an antiseptic, a biological preparation and a chinese medicine. Another mode is that the effects of a medicine are applied through a graft chain provided on the surface of the capsule endoscope. <P>COPYRIGHT: (C)2007,JPO&INPIT

Description

  The present invention relates to a capsule endoscope having a medicinal component on at least a part of its surface and having improved functionality and usefulness.

Endoscopy is widely used as a useful means for finding esophageal cancer, gastric cancer and the like. However, in the endoscopy, since an endoscope, which is a tube-shaped foreign substance, is inserted into the oral cavity, the pain given to the patient such as vomiting at the time of the examination was not without.
On the other hand, capsule endoscopes are about the same size as medicine capsules, and inspecting the mouth of the esophagus, stomach, intestines, etc. by drinking endoscope capsules like drinking medicine capsules Will be able to. By remotely operating the endoscope capsule from outside the body, it is possible to reduce the burden on the patient and obtain necessary in-vivo information.

By the way, an endoscope, which is a medical device used in a living body, must have high affinity with the living body. For this reason, there is a water-repellent fluorine-containing polymer as one of the widely used materials because of its insensitivity and non-invasiveness with living cells, and a tube-like endoscope whose surface is covered with this fluorine-containing polymer is proposed. (See Patent Document 1).
In addition, it is known that both insensitivity and non-invasiveness with living cells can be achieved by introducing a phosphorylcholine derivative having a living body-like structure into medical materials such as catheters, endoscopes, and contact lenses (Patent Literature). 2).

  Therefore, it is considered useful to coat the entire surface of the capsule endoscope using these materials. However, the capsule endoscope has excellent anti-contamination properties against blood and proteins, and is performed remotely from outside the body. Therefore, it is required that posture control, motion control, and position control be easy. Moreover, if the capsule endoscope can hold a medicinal component on the surface and can be released at a target site in a living body, it can be used for treatment, and its usefulness is further increased, so that development is desired at present. is there.

Japanese translation of PCT publication No. 2004-524081 Japanese Patent Laid-Open No. 10-176021

  An object of the present invention is to solve the above-described problems and achieve the following objects. That is, the present invention has a medicinal component on at least a part of the surface, can perform effective treatment and inspection, has excellent anti-contamination properties against blood and proteins, and controls posture, movement, and position. An object of the present invention is to provide a capsule endoscope that is easy to handle.

Means for solving the above problems are as follows. That is,
<1> A capsule endoscope having a medicinal component on at least a part of a surface of the capsule endoscope. In the capsule endoscope according to <1>, since it has a medicinal component on at least a part of its surface, the medicinal component can be directly administered to a target site (affected site) in a living body. Since the inspection can be performed, the usefulness is further increased.
<2> Medicinal ingredients include peripheral nerve agents, central nervous agents, hormone agents, autocidal, cardiovascular agents, respiratory agents, digestive agents, urogenital agents, skin agents, The capsule endoscope according to <1>, wherein the capsule endoscope is at least one selected from vitamins, chemotherapeutic agents, antiseptics, preservatives, biological preparations, and traditional Chinese medicines.
<3> The capsule endoscope according to any one of <1> to <2>, wherein the capsule endoscope has a medicinal component via a graft chain provided on a surface of the capsule endoscope. In the capsule endoscope according to <3>, since it has a medicinal component via a graft chain provided on the surface of the capsule endoscope, the medicinal component can be easily bonded (supported) to the surface. it can.
<4> The capsule endoscope according to <3>, wherein the medicinal component is bonded to the graft chain by an ionic bond.
<5> The capsule endoscope according to any one of <1> to <4>, wherein the medicinal component is detachable from the graft chain at a target site in a living body.
<6> The capsule endoscope according to any one of <3> to <5>, wherein the graft chain is formed in a pattern on the surface of the capsule endoscope.

<7> The capsule endoscope according to any one of <3> to <6>, wherein the graft chain is obtained by polymerizing at least a fluorine-containing compound.
<8> The capsule endoscope according to <7>, wherein the fluorine-containing compound has a polymerizable group.
In the capsule endoscope according to any one of <7> to <8>, a pattern is formed with a fluorine resin having a low surface energy and a high water repellency by surface grafting a fluorine-containing compound by a radical polymerization method. Therefore, it has the ability to prevent cell attachment and contamination.

<9> The capsule endoscope according to any one of <3> to <6>, wherein the graft chain is obtained by polymerizing at least a phosphorylcholine group-containing compound.
<10> The capsule endoscope according to <9>, wherein the phosphorylcholine group-containing compound has a polymerizable group.
In the capsule endoscope according to any one of <9> to <10>, adsorption and denaturation of biological components such as proteins can be suppressed by surface grafting a phosphorylcholine group-containing compound by radical polymerization. It has biocompatibility and excellent antifouling properties.

  According to the present invention, conventional problems can be solved, and at least a part of the surface has a medicinal component, and effective treatment and inspection can be performed at a target site in a living body, and contamination prevention such as blood and protein can be prevented. In addition, it is possible to provide a capsule endoscope that is excellent in posture control, movement control, and position control.

(Capsule endoscope)
The capsule endoscope of the present invention is characterized by having a medicinal component on at least a part of the surface of the capsule endoscope.

-Capsule endoscope-
The capsule endoscope is not particularly limited in size, shape, material, performance, etc., and can be appropriately selected according to the purpose. For example, FIG. 1 shows a first embodiment of the present invention. FIG. 2 is an enlarged longitudinal sectional view showing an outline of the configuration inside the casing of the capsule endoscope, and FIG. 2 is an enlarged front view of a main part when the capsule endoscope of FIG.

As shown in FIG. 1, a capsule endoscope 100 has a casing 10 that is an exterior part made of a capsule-shaped resin or the like whose outer shape is a capsule-shaped tablet shape and whose longitudinal section has a substantially oval shape. The front part is formed of a transparent member 10a.
The material of the casing 10 is not particularly limited, and can be appropriately selected from those commonly used for capsule endoscopes according to the purpose. For example, any of inorganic materials and organic materials can be used. Can be used.
Examples of the inorganic material include glass, silicon, aluminum, stainless steel, gold, silver, zinc, copper, ITO, tin oxide, alumina, and titanium oxide.
Examples of the organic material include polyethylene resin, polypropylene resin, polystyrene resin, cellulose diacetate, cellulose triacetate, cellulose propionate, cellulose butyrate, cellulose acetate butyrate, cellulose nitrate, polyethylene terephthalate resin, polycarbonate resin, and polyvinyl acetal. Examples thereof include resins, polyurethane resins, epoxy resins, polyester resins, acrylic resins, polyimide resins, and the like.
In addition, in order to improve the bonding property with the polymerization initiator, the organic material may be a material in which a functional group such as a hydroxyl group or a carboxyl group is introduced to the surface by corona treatment, plasma treatment, or the like.

  An objective lens 1a that is disposed inside the casing 10 of the capsule endoscope at a front portion facing the transparent member 10a and forms an optical image of a subject to be imaged such as a digestive organ in a body cavity. A lens barrel 1 that holds the light source, and an illumination light source unit (hereinafter referred to as “light source”) that is disposed on the outer peripheral surface of the lens barrel 1 and illuminates a subject to be imaged such as a digestive organ in a body cavity, for example, an LED 2), an electronic control component 3 constituting a control circuit for controlling the driving of the light source 2, and a light receiving surface 4a, and a light receiving surface by a drive signal from a driver circuit of a peripheral circuit board 6 described later. 4a for performing a predetermined photoelectric conversion process on the light incident on the light 4a and outputting an image signal, for example, a solid-state image pickup device (hereinafter also referred to as “image pickup device”) 4 composed of a CCD or CMOS sensor, and a focus adjustment Element frame 5 and after image sensor 4 And a peripheral circuit such as a driver circuit that performs drive control of the image sensor 4, a communication circuit that transmits and outputs a captured image signal outside the body cavity, and a control circuit that performs drive control of the entire capsule endoscope 100. For example, a peripheral circuit board 6 made of a rigid board, a flexible board (flexible board) 7 which is a three-dimensional wiring member on which circuit elements are mounted, a light source 2 and an electronic control component 3 via the flexible board 7 A power supply 8 configured to supply electric power to the imaging device 4 and peripheral circuits, for example, a battery, is disposed, and the main part of the capsule endoscope 100 is configured.

  In addition, the element frame 5 is continuously arrange | positioned so that the peripheral part of the light-receiving surface 4a of the front surface of the image pick-up element 4 may be covered. Further, it is formed of a resin wiring board that is a three-dimensional wiring member so as to protrude forward and fit with the inner peripheral surface of the lens barrel 1, and focus adjustment between the image sensor 4 and the objective lens 1 during assembly. It serves to adjust the distance for.

  The peripheral circuit board 6 and the power supply 8 are formed on the back surface or the front surface of the flexible circuit board 7 that is appropriately bent inside the housing 10 as necessary so that the peripheral circuit board 6 and the power supply 8 can be efficiently placed inside the housing 10. For example, the contact terminal is electrically connected by solder or conductive adhesive. The lens barrel 1 is electrically connected to the flexible substrate 7 by being integrally formed as will be described later. Further, the electronic control component 3 is electrically connected and fixed to the flexible substrate 7 by the conductive adhesive. The driver circuit, the communication circuit, and the control circuit of the peripheral circuit board 6 are electrically connected to each other via a conductive material 6a such as solder or Au (gold) protrusion, The image sensor 4 is electrically connected by wire bonding or the like via the conductive wire 6b. Further, the lens barrel 1 and the element frame 5 are electrically connected and fixed via the conductive material or conductive wire. The image pickup device 4 is fixed to the peripheral circuit board 6 by the conductive adhesive or the insulating adhesive, and the element frame 5 is fixed to the light receiving surface 4a of the image pickup device 4 by a light-shielding adhesive. .

  The lens barrel 1 is formed of a resin wiring board (hereinafter, referred to as MID; (Molded Interconnect Devices)), which is a three-dimensional wiring member, on which circuit elements are mounted. As shown in FIG. 2, one or more light sources 2 and electronic control components 3 are electrically connected and fixed by the conductive adhesive. Further, one end of the flexible substrate 7 is electrically connected and fixed to the outer peripheral surface of the lens barrel 1 by integrally forming the lens barrel and the flexible substrate 7 in the same process using insert molding. The lens barrel 1 and the flexible substrate 7 may be electrically connected by fixing the flexible substrate 7 to the contact terminal of the lens barrel 1 made of MID with the conductive adhesive.

  As described above, in the capsule endoscope 100 according to the present embodiment, the light source 2 is disposed on the outer peripheral surface of the lens barrel 1 made of MID on which circuit elements are formed and fixed. Further, the electronic control component 3 for controlling the driving of the light source 2 is disposed and fixed to the lens barrel 1 and the flexible substrate 7 formed integrally with the lens barrel 1. And the flexible substrate 7 was arrange | positioned in the space which was not used until now.

  Therefore, the lens barrel 1 and the flexible substrate 7 formed integrally with the lens barrel 1 can be used as a circuit board, and the light source 2 and the electronic control component 3 for controlling the drive of the light source 2 are disposed and fixed. Since it is not necessary to provide a separate substrate in the housing 10, the light source 2 and the electronic control component 3 can be disposed in the housing 10 with a high mounting density.

  As a result, the mounting space for the light source 2 can be reduced in size, so that an internal space formed by the light source 2 and the casing 10 facing the light source 2 can be secured widely. Since the external power feeding component, the component for controlling the position of the capsule endoscope itself, and the like can be disposed, a plurality of electric circuit boards having a high mounting density and formed with more various components and circuit elements are provided. It becomes possible to arrange | position in a housing | casing.

  In addition, by disposing the flexible substrate 7 in a dead space such as between the casing 10 and the peripheral circuit substrate that have not been used so far, the lens barrel 1 and the peripheral circuit substrate 6 that are connected and fixed to the flexible substrate 7. The power source 8 can also be arranged with a high mounting density. Therefore, the capsule endoscope itself can be reduced in size, the number of parts can be reduced, the assembly can be facilitated, and interference between the separately arranged board and other components and the inner wall of the housing can be prevented. Can do.

  Further, by fixing the light source 2 to the lens barrel 1, there is an advantage that the irradiation position is not easily shaken, and the illumination angle can be freely changed by simply moving the lens barrel 1.

  In the present embodiment, the peripheral circuit board 6 on which the peripheral circuit composed of the driver circuit, the communication circuit, the control circuit, etc. is mounted is a rigid board, but this is a lens barrel. Similarly to 1, it may be formed of MID. In this case, the conductive material 6a may be formed integrally with the peripheral circuit board 6 by insert molding.

The power source 8 is constituted by a battery. However, the power source 8 is not limited to this, and a capacitor, external power supply by wireless communication may be used, or the light source 2, the electronic control component 3, the image sensor 4, and the peripheral circuit board 6 may be used. Any device can be used as long as it can supply predetermined power and can be built in the housing 10.
Further, although the element frame 5 is configured to fit the inner peripheral surface of the lens barrel 1 at the front end thereof, the element frame 5 may be fitted to the outer peripheral surface of the lens barrel 1.

-Medicinal component-
The medicinal component is not particularly limited and may be appropriately selected depending on the intended purpose. For example, a peripheral nerve agent, a central nerve agent, a hormonal agent, an otacoid, a circulatory agent, a respiratory agent Gastrointestinal agents, urogenital agents, skin agents, vitamins, chemotherapeutic agents, antiseptics, preservatives, biological agents, Chinese herbal medicines, and the like. These may be used individually by 1 type and may use 2 or more types together.

  The peripheral nerve agent is not particularly limited and may be appropriately selected depending on the intended purpose. Examples thereof include a local anesthetic, a muscle relaxant, and an autonomic nervous system agent.

  There is no restriction | limiting in particular as said local anesthetic, According to the objective, it can select suitably, For example, cocaine, tropopacaine, procaine, lidocaine, bupivacaine, mepivacaine, tetracaine, dibucaine etc. are mentioned.

  There is no restriction | limiting in particular as said muscle relaxant, According to the objective, it can select suitably, For example, d-tubocurale, galamine, pancuronium, vecuronium, decamethonium, susamethonium, dantroline, etc. are mentioned.

  The autonomic nervous agent is not particularly limited and may be appropriately selected depending on the intended purpose.For example, epinephrine, norepinephrine, isoproterenol, dopamine, phenylephrine, methoxamine, clonidine, metallaminol, naphazoline, dobutamine , Methoxyphenamine, orciprenaline, terbutaline, chlorprenalin, trimethoquinol, salbutamol, tulobenol, procaterol, pyrbuterol, fenoterol, formotenol, clenbuterol, mabuterol, tyramine, ephedrine, methylephedrine, amphetamine, ergotamine, ergotamine, ergotamine Dihydroergotoxin, Dihydroergotoxin, Phenoxybenzamine, Trazoline, Phentolamine, Prazosi , Terazosin, doxazosin, bunazosin, urapidil, yohimbine, propranolol, bupranolol, bufetrol, bucmolol, nadolol, timolol, chillisolol, practolol, metoprolol, atenolol, bisoprolol, betaxolol, pindolol, oxprenolol, olprenolol, olprenolol Indenolol, penbutolol, bunitrol, bopindolol acebutolol, seriprolol, rabetanol, guanethidine, methyldopa, clonidine, guanfacine, guanabenz, acetylcholine, benatechol, methacholine, muscarine, pilocarpine, physostigmine, neostigmine, nodrophonium anthronium , Scopolamine, low Extract, homatropine, cyclopentolate, nicotinic, DMPP, TMA, DFP, TEPP, tetraethylammonium, hexamethonium, mecamylamine, trimethaphan, and the like.

  The central nervous agent is not particularly limited and may be appropriately selected depending on the intended purpose.For example, methoxyflurane, enflurane, isoflurane, sevoflurane, thiopental, thiamylal, hexovalpital, pentovalpital, Propanicid, ketamine, phenobarbital, bromvaleryl urea, bromodiethylacetylurea, glutethimide, methaquaron, nitrazepam, flurazepam, estazolam, triazolam, ethylparafinol, ethochlorbinol, ethyl alcohol, disulfiram, phenytoin, mephenytoin, esotoin Pital, Netarbital, Primidone, Carbamazepine, Zonisamide, Trimetadione, Parameterdione, Sodium Valproate, Fenceximide, Methos Cymid, ethosomic, diazepam, clonazepam, morphine, codeine, devine, papaverine, noscapine, opium tincture, codeine phosphate, heroin, pethidine, fentanyl, methadone, levorphanol, dextromethorphan, pentazocine, phenazosin, buprenorphan, butorphanol, Nalolphine, levalorphan, naloxone, endorphin, mephenesin, epolizone, baclofen, tizanidine, levodopa, carbidopa, benzeraside, trihexyphenidyl, biperidene, benztropine, amantadine, bromocriptine, pergolide, droxidopa, stroxine pendine, stritoxine , Caffeine, theophylline, theobromine, aminoph Phosphorus, chlorbromazine, thioridazine, ferfenadine, reserpine, resinamine, deserpidine, haloperidol, chlorprothixene, thiothixene, iproniazide, niaramide, isocarboxazide, safradine, tranylpipromine, purgerin, imipramine, desipramine, amitriptyline , Mianserin, diazepam, oxazepam, nitrazepam, etizolam, lorazepam, hydroxyzine, mescaline, dimethyltryptamine, diethyltryptamine, psylosin, psirocibin, bufotenin, hermin and the like.

  The hormonal agent is not particularly limited as long as it has hormonal action or inhibits it, and can be appropriately selected according to the purpose. For example, growth hormone, thyroid stimulating hormone, adrenocorticotropic hormone, follicle Stimulating hormone, luteinizing hormone, lactating hormone, oxytocin, vasopressin, thyroid hormone, liothyronine sodium, levothyroxine sodium, methylthiouracil, propylthiouracil, thiamazole, calcitonin, parathyroid hormone, insulin, glucagon, carbutamide, Chlorpropamide, acetohexamide, tolazamide, hetahexamide, 1-butyl-3-nitrourea, tolbutamide, glibenguramide, grimidine, glybsol, phenformin, buformin, metformin, Palrestat, voglibose, acarnose, troglitazone, cortisone, hydrocortisone, desoxycorton, prednisolone, ethylprednisolone, parameterzone, dexamethasone, betamethasone, aldosterone, estradiol, estrone, ethinyl estradiol, stilbene, progesterone, chlorandazilone test, norestelon test Examples include sterolone, etiocholanolone, epiandrosterone, methyltestosterone, oxymetholone, methenolone, mixed hormone drugs, and the like.

  The ootachoid is not particularly limited and may be appropriately selected depending on the intended purpose.For example, histamine, diphenhydramine, diphenylpyralin, clemastine, pyrilamine, promethazine, chlorpheniramine, chlorcyclidine, cyproheprazine, mequitazine, terfenadine, Cimetidine, ranitidine, famotidine, diphenhydramine, dimenhydrinate, cyclidine, meclizine, promethazine, chetylperazine, serotonin, methysergide, proheptazine, renin, angiotensin, captopril, prostaglandin F2, α, prostaglandin A2 , Leukotriene, bradykinin, plasma kallikrein, glandular kallikrein, sodium salicylate, Pyrin, salicylic amide, indomethacin, mefenamic acid, flufenamic acid, diclofenac, benzidamine, epilysole, thiaramide, phenacetin, acetaminophen, antipyrine, aminopyrine, sulpyrine, colchicine, probenecid, allopurinol, phenylbutazone, oxyphenbutazone, sulfinbuta Zon, dexamethasone, betamethasone, auranofin, penicillamine, azathioprine, bucillamine, salazosulfapyridine, actarit and the like.

  The circulatory system agonist is not particularly limited and may be appropriately selected depending on the intended purpose. , Polossilarid, ouabain, amrinone, pimobendan, vesnarinone, quinidine, procainamide, disopyramide, mexiletine, aplidine, propaphenone, flecainide, pilsicainide, amiodarone, verapamil, hydralazine, diazoxide, prazosin, reserpine, guazatide Enalapril, alaspril, delapril, cilazapril, lisinopril, benazepril, imidapril, democapril, quinapril, trandolap , Amyl nitrite, nitroglycerin, isosorbide mononitrate, isosorbide dinitrate, pentaerythritol tetranitrate, molosidemine, nicorandil, dipyridamole, diserap, prenylamine, chromonal, trimetazidine, oxyfedonaline, etaphenone nifedipine, nicardipine, nitrendipine , Benidipine, Manidipine, Varnidipine, Efonidipine, Amlodipine, Felodipine, Diltiazem, Verapamil, Inositol Hexanicotylate, Cyclendrate, Cinnarizine, Inkspurin, Alprostadil, Meclofenoxate, Vinpocetine, Nicergoline, Ibucilast, Flunarizine, Ifenprodil Pentoxifylline, Indebenone, Indeloxazine, Biferamine, P Pentophyrin, nicotinic acid, cholestyramine, probucol, pravastatin, simvastatin, heparin, dicamalol, tolmexan, warphirin, urokinase, streptokinase, tissue plasminogen activator, ticlopidine, cilostazol, ethyl icosampenate, beraprost, thrombin, tranexamic acid, Carbazochrome, erythropoietin, epoetin alfa, epoetin beta, filgrastim, lenograstim, narutograstim, mirimostim, sildenafil citrate, and the like.

  The respiratory system agent is not particularly limited and may be appropriately selected depending on the intended purpose.For example, dimorpholine, dimephrine, doxapram, saponins, non-saponin glycosides, bromhexine, methylcysteine, ethylcysteine , Acetylcysteine, carbocysteine, ambroxol, xanthine derivatives, sodium cromoglycate, ketotifen, tranilast, azelastine, oxatomide, ozagrel, suplatast tosylate, terfenadine, astemizole, seratrodast, pranlukast hydrate, and the like.

  The digestive system agent is not particularly limited and may be appropriately selected depending on the intended purpose.For example, pirenzepine, thixidium, cimetidine, famotidine, ranitidine, omeprazole, lansoprazole, methylmethionine sulfonium chloride, azulene sulfonic acid, sucralfate , Aldioxa, gefarnate, teprenone, troxipide, irsogladine, sulpiride, sofalcone, prunotol, rebamipide, benexate betadex, ornoprostil, misoprostol, enprostil, clarithromycin, amoxicillin, metronidazole, castor oil, anthraquinone derivatives, Phenolphthalein, Picosulfate, Glycerin, Bisacodyl, Albumin tannate, Opium alkaloid, Berberi , Rakutomin, metoclopramide, domperidone, cisapride, trimebutine, and the like.

  The urogenital agent is not particularly limited and may be appropriately selected depending on the intended purpose. For example, D-mannitol, acetazolamide, dichlorophenamide, trichloromethiazide, hydrochlorothiazide, benzylhydrochlorothiazide, Penflutizide, methycrothiazide, metolazone, chlorthalidone, furosemide, ethacrynic acid, piretanide, bumethamide, azosemide, mefluside, spitonolactone, triamterene, canrenoic acid potassium, hexamine, mandelic acid, nitrofurantoin, ergotoxin, ergotamine, ergometri, And methyl ergomethrin, oxytocin, dinoprost, dinoprostone, gemeprost, spartein, oxyhinoline sulfate, and the like.

  The skin (mucosal) agent is not particularly limited and may be appropriately selected depending on the intended purpose. , Starch, methylcellulose, glycerin, propylene glycol, olive oil, camellia oil, sesame oil, rapeseed oil, soybean oil, peanut oil, corn oil, coconut oil, stearic acid, beef tallow, pork fat, lanolin, paraffin, petrolatum, honey Wax, talc, kaolin, stone pine, fibrinogen, thromboplastin, absorbable gelatin sponge, oxidized cellulose, methoxalene, monobenzone, and the like.

  There is no restriction | limiting in particular as said vitamin agent, According to the objective, it can select suitably, For example, vitamin A, vitamin D, vitamin E, vitamin F, vitamin K, ubiquinone, thiamine, riboflavin, pyridoxine, pantothenic acid, α-lipoic acid, bithion, folic acid, mezoinotitol, p-aminobenzoic acid, cyanocobalamin, prosultiamine, fursultiamine, octotiamine, bisbenchamine, benfotiamine, chicotiamine, dicetiamine, ascorbic acid, vitamin P, Etc.

  The chemotherapeutic agent is not particularly limited and may be appropriately selected depending on the intended purpose.For example, penicillins, cephems, oxacephems, monopactams, carpapenems, β-lactamase inhibitors, fosfomycin, amino compounds Glycosides, chloramphenicol, tetracyclines, macrolides, lincomycins, rifamycin, antimycobacteria, polyene macrolides, sulfa drugs, quinolones, vitarabine, idoxuridine, acyclovir, ganciclovir, zidobusine , Didanodine, interferon, amantadine, emetine, pyrimethamine, chloroquine, primaquine, quinacrine, metronidazole, pentamidine isethionate, santonin, kainic acid, piperazine salt, pyrantel pamoate, praziquantel Camara, diethylcarbamazine, hexyl resorcin, niclosamide, biotinol, bephenium hydroxynaphthoate, pyrunium pamoate, isothianiide, streptomycin, rifampicin, ethambutol, paraaminosalicylic acid, mechlorethamine hydrochloride, cyclophosphamide, melphalan, thiotepa, busulfan , Nimustine, methotrexate, 6-mercaptopurine, 5-fluorouracil, cytarabine, diethylstilbestrol, ethinyl estradiol, testosterone propionate, fluoxymesterone, claosterone, hydrocortisone, prednisolone, prednisone, dexamethasone, tamoxifen citrate, Toremifene citrate, actinomycin D, doxorubicin, da Unobisin, aclarubicin, epirubicin, pirarubicin, bleomycin, peomycin, mitomycin C, vinblastine, vindesine, etoposide, irinotecan, pentostatin, cisplatin, tretinoin, bicibanil, krestin, oseltamivir phosphate, and the like.

  The biological product is not particularly limited and may be appropriately selected depending on the purpose. For example, pertussis, diphtheria, tetanus mixed vaccine, oral live polio vaccine, dry attenuated rubella vaccine, dry attenuated measles vaccine, influenza HA vaccine , Japanese encephalitis vaccine, dry BCG vaccine, pressure ulcer vaccine, cholera vaccine, Weil disease fall plague mixed vaccine, tetanus toxoid, diphtheria toxoid, gas gangrene antitoxin, diphtheria antitoxin, snake antitoxin, tetanus antitoxin, purified tuberculin, BCG, and the like.

  The herbal medicine is not particularly limited and may be appropriately selected depending on the intended purpose.For example, Annaka-san, Cho-to-san, Hokuren-do-to, Keishi-gan-maru, Sho-ji-ko-to, Yokukansan, Hachimi-ji Houmaru, Kakkonyu, etc.

  The medicinal component is preferably bonded to a graft chain provided on the surface of the capsule endoscope, and the bond between the medicinal component and the graft chain is not particularly limited and may be appropriately selected depending on the purpose. For example, an ionic bond, a covalent bond, and the like can be mentioned, but an ionic bond is preferable because it is easy to desorb a medicinal component from the graft chain due to environmental factors.

  It is preferable that the medicinal component can be easily detached from the graft chain at a target site (for example, an affected area) in a living body. There is no restriction | limiting in particular as this detachment | leave method, According to the objective, it can select suitably, For example, pH change, electrical stimulation, light stimulation, etc. are mentioned.

-Graft chain-
The graft chain is preferably formed in a pattern on the surface of the capsule endoscope because different surface properties can be imparted to the capsule endoscope.

  The graft chain is not particularly limited and may be appropriately selected depending on the purpose, but is preferably obtained by polymerizing a compound having a reactive group.

  The compound having a reactive group is not particularly limited and may be appropriately selected depending on the intended purpose. Examples thereof include styrene monomers such as styrene, methylstyrene, chloromethylstyrene, and aminostyrene; ) Acrylate, ethyl (meth) acrylate, butyl (meth) acrylate, dodecyl (meth) acrylate, cetyl (meth) acrylate, stearyl (meth) acrylate, cyclohexyl (meth) acrylate, 2-ethylhexyl (meth) acrylate, etc. Alkyl (meth) acrylates; (meth) acrylates containing reactive functional groups such as (meth) acryloyloxyethyltrimethoxysilane; 2- (meth) acryloyloxyethylbutyl urethane, 2- (meth) acryloyloxyethylbenzyl urethane, 2 -(Meth) acryloyloxyethyl Urethane-modified (meth) acrylates such as phenyl urethane; vinyl ethers such as methyl vinyl ether, ethyl vinyl ether and butyl vinyl ether; vinyl esters such as vinyl acetate; halogen-substituted or unsubstituted such as vinyl chloride, vinylidene chloride, ethylene, propylene and isobutylene Hydrocarbon monomers; polyfunctional ester type monomers such as diethyl fumarate and diethyl malate; (meth) acrylic acid, aconitic acid, itaconic acid, metaconic acid, citraconic acid, fumaric acid, maleic acid, metaconic acid, etc. Carboxyl group-containing monomers of sulfonic acid monomers such as vinyl sulfonic acid, acrylamide-2-methylpropane sulfonic acid and vinyl sulfonic acid, and various metal salts thereof; N, N-dimethylaminopropyl (meth) Acrylamide, N, N-dimethyl Nitrogen-containing monomers such as aminoethyl (meth) acrylate and N, N-diethylaminoethyl (meth) acrylate, and various quaternary salts thereof; 2-vinylpyridine, 3-vinylpyridine, 4-vinylpyridine, 2- Vinylimidazole, N-methyl-2-vinylimidazole, N-vinylimidazole, (meth) acrylamide, N-methyl (meth) acrylamide, N, N-dimethyl (meth) acrylamide, N-ethyl (meth) acrylamide, N- Amide type monomers such as isopropyl (meth) acrylamide, Nt-butyl (meth) acrylamide, N- [tris (hydroxymethyl) methyl] acramide; 2-hydroxyethyl (meth) acrylate, 2,3-dihydroxypropyl Water such as (meth) acrylate, 1,3-dihydroxypropyl (meth) acrylate Group-containing monomer; polyethylene glycol (meth) acrylate; nitrogen-containing cyclic monomer such as N-vinylpyrrolidone, N- (meth) acryloylpyrrolidone, acryloylmorpholine, maleic imide, maleic anhydride, acrylonitrile, vinylbenzylamine And various hydrophobic macromonomers and various hydrophilic macromonomers. These may be used individually by 1 type and may use 2 or more types together.

The graft chain is preferably obtained by polymerizing at least a fluorine-containing compound.
The fluorine-containing compound preferably has a polymerizable group other than fluorine. Examples of the polymerizable group include a group having a non-aromatic unsaturated carbon-carbon bond (double bond or triple bond). Among these, an ethylenically unsaturated group is preferable.
As said ethylenically unsaturated group, a C2-C20 thing is preferable, A C2-C15 thing is more preferable, A C2-C10 thing is still more preferable, for example, (meth) acryloyl group, (meth) acryloyloxy A propyl group, a vinyl group, a vinyloxy group, an allyl group, a cinnamoyl group, etc. are mentioned.
As the ring-opening polymerizable group, those having 2 to 20 carbon atoms are preferable, those having 2 to 15 are more preferable, those having 2 to 10 are more preferable, and examples thereof include an epoxy group, an oxetanyl group, and an oxazolyl group. Can be mentioned.

Examples of the fluorine-containing compound include a fluorine monomer, a polymer of the fluorine monomer, a copolymer of a fluorine monomer and another monomer, or a mixture thereof.
Among these, the fluorine monomer is particularly preferable because it can be chemically bonded directly by radical species generated on the surface of the capsule endoscope by light irradiation and can impart hydrophobicity to at least a part of the capsule endoscope. .
As the fluorine monomer, a monomer containing two or more fluorine atoms in one molecule is preferable, and what is generally called a perfluoro group is particularly preferable.

  Suitable examples of the fluorine monomer include at least one selected from compounds represented by the following structural formulas (1), (2), (3), (4) and (5).

_{^{CH 2 = CR 1 COOR 2 Rf}} ··· structural formula (1)
However, in the structural formula (1), R ¹ represents a hydrogen atom or a methyl group.
R ² _{is, -C p H 2p -, -} C (C p H 2p + 1) H -, - CH 2 C (C p H 2p + 1) H-, or an _-CH 2 _CH 2 O-.
Rf _{is, -C n F 2n + 1,} - (CF 2) n H, -C n F 2n + 1 -CF 3, - (CF 2) p OC n H 2n C i F 2i + 1, - (CF 2) p OC m H _2m C _i F _{2i H,} represents a _{-N (C p H 2p + 1} ) COC n F 2n + 1, -N (C p H 2p + 1) SO 2 C n F 2n + 1. However, in Rf, p represents 1 to 10, n represents 1 to 16, m represents 0 to 10, and i represents an integer of 0 to 16, respectively.

CF ₂ = CFORg ... Structural formula (2)
However, in said structural formula (2), Rg represents a C1-C20 fluoroalkyl group.

CH ₂ = CHRg ... Structural formula (3)
However, in said structural formula (3), Rg represents a C1-C20 fluoroalkyl group.

CH 2 = CR 3 COOR 5 R j R 6 OCOCR 4 = CH 2 ··· structural formula (4)
In the Structural Formula (4), R 3 and R 4 represents a hydrogen atom, or a methyl group. R 5, and R 6, -C q H 2q -, - C (C q H 2q + 1) H -, - CH 2 C (C q H 2q + 1) H- or -CH 2 CH 2 O-, R j is It represents the -C t F 2t. q is an integer of 1 to 10, and t is an integer of 1 to 16.

^{_{CH 2 = CHR 7 COOCH 2 (}} CH 2 R k) CHOCOCR 8 = CH 2 ··· structural formula (5)
In the Structural Formula (5), ^{R 7} and ^{R 8} represents a hydrogen atom, or a methyl group. R _k is —C _y F _{2y + 1} . y is an integer of 1-16.

Examples of the monomer represented by the structural formula (1) include CF ₃ (CF ₂ ) ₅ CH ₂ CH ₂ OCOCH═CH ₂ , CF ₃ CH ₂ OCOCH═CH ₂ , and CF ₃ (CF ₂ ) _{4. CH 2 CH 2 OCOC (CH 3} ) = CH 2, C 7 F 15 CON (C 2 H 5) CH 2 OCOC (CH 3) = CH 2, CF 3 (CF 2) 7 SO 2 N (CH 2) CH ₂ CH ₂ OCOCH═CH ₂ , CF ₂ (CF ₂ ) ₇ SO ₂ N (C ₃ H ₇ ) CH ₂ CH ₂ OCOCH═CH ₂ , C ₂ F ₅ SO ₂ N (C ₃ H ₇ ) CH ₂ CH ₂ OCOC (CH ₃ ) ═CH ₂ , (CF ₃ ) ₂ CF (CF ₂ ) ₆ (CH ₂ ) ₃ OCOCH═CH ₂ , (CF ₃ ) ₂ CF (CF ₂ ) ₁₀ (CH ₂ ) ₃ OCOC (CH ₃ ) = C _{2, CF 3 (CF 2)} 4 CH (CH 3) OCOC (CH 3) = CH 2, CF 3 CH 2 OCH 2 CH 2 OCOCH = CH 2, C 2 F 5 (CH 2 CH 2 O) 2 CH 2 OCOCH═CH ₂ , (CF ₃ ) ₂ CFO (CH ₂ ) ₅ OCOCH═CH ₂ , CF ₃ (CF ₂ ) ₄ OCH ₂ CH ₂ OCOC (CH ₃ ) ═CH ₂ , C ₂ F ₅ CON (C ₂ H _{5) CH 2 OCOCH = CH 2} , CF 3 (CF 2) 2 CON (CH 3) CH (CH 3) CH 2 OCOCH = CH 2, H (CF 2) 6 C (C 2 H 5) OCOC (CH 3 _{) = CH 2, H (CF} 2) 8 CH 2 OCOCH = CH 2, H (CF 2) 4 CH 2 OCOCH = CH 2, H (CF 2) CH 2 OCOC (CH 3) = CH 2, _{F 3 (CF 2) 7 SO} 2 N (CH 3) CH 2 CH 2 OCOC (CH 3) = CH 2, CF 3 (CF 2) 7 SO 2 N (CH 3) (CH 2) 10 OCOCH = CH 2 _{, C 2 F 5 SO 2 N} (C 2 H 5) CH 2 CH 2 OCOC (CH 3) = CH 2, CF 3 (CF 2) 7 SO 2 N (CH 3) (CH 2) 4 OCOCH = CH 2 , C ₂ F ₅ SO ₂ N (C ₂ H ₅ ) C (C ₂ H ₅ ) HCH ₂ OCOCH═CH ₂ , and the like. These may be used individually by 1 type and may use 2 or more types together.

Examples of the fluoroalkylated olefin represented by the structural formula (2) or (3) include C ₃ F ₇ CH═CH ₂ , C ₄ F ₉ CH═CH ₂ , C ₁₀ F ₂₁ CH═CH ₂ , _{C 3 F 7 OCF = CF 2} , C 7 F 15 OCF = CF 2, C 8 F 17 OCF = CF 2, and the like.

Examples of the monomer represented by the structural formula (4) or (5), for _{example, CH 2 = CHCOOCH 2 (CF} 2) 3 CH 2 OCOCH = CH 2, CH 2 = CHCOOCH 2 CH (CH 2 C 8 F ₁₇ ) OCOCH═CH ₂ , and the like.

  The other monomer is not particularly limited as long as it is capable of radical polymerization, and can be appropriately selected according to the purpose. For example, (meth) acrylic acid, maleic acid, fumaric acid, itaconic acid, etc. Examples include saturated carboxylic acids, glycidyl esters, styrene, vinyl esters of alkyl acids, silicon-containing monomers, and the like. The addition amount of the other monomer is preferably 50% by mass or less based on the fluorine monomer.

The graft chain is preferably obtained by polymerizing at least a phosphorylcholine group-containing compound.
The phosphorylcholine group-containing compound preferably has a polymerizable group in addition to the phosphorylcholine group. Examples of the polymerizable group include a group having a non-aromatic unsaturated carbon-carbon bond (double bond or triple bond). Among these, an ethylenically unsaturated group is preferable.
As said ethylenically unsaturated group, a C2-C20 thing is preferable, A C2-C15 thing is more preferable, A C2-C10 thing is still more preferable, for example, (meth) acryloyl group, (meth) acryloyloxy A propyl group, a vinyl group, a vinyloxy group, an allyl group, a cinnamoyl group, etc. are mentioned.
As the ring-opening polymerizable group, those having 2 to 20 carbon atoms are preferable, those having 2 to 15 are more preferable, those having 2 to 10 are more preferable, and examples thereof include an epoxy group, an oxetanyl group, and an oxazolyl group. Can be mentioned.

Examples of the phosphorylcholine group-containing compound include those described in JP-A No. 58-154591, Polymer Journal, Vol. 22, pages 335-360 (1990), and the like.
Specific examples include 2-methacryloyloxyethyl phosphoriccholine, 3-methacryloyloxypropyl phosphorylcholine, 2-acryloyloxyethyl phosphorylcholine, 3-acryloyloxypropyl phosphorylcholine, and among these, Royoxyethyl phosphoric choline is particularly preferred.

Copolymers of the phosphorylcholine group-containing compound and other monomers can also be used.
The other monomer is not particularly limited as long as it is capable of radical polymerization, and can be appropriately selected according to the purpose. For example, (meth) acrylic acid, maleic acid, fumaric acid, itaconic acid, etc. Examples include saturated carboxylic acids, glycidyl esters, styrene, vinyl esters of alkyl acids, silicon-containing monomers, and the like. The amount of the other monomer added is preferably 50% by mass or less based on the phosphorylcholine group-containing compound.

  The capsule endoscope preferably has a graft chain formed in a pattern on the surface thereof, and the pattern is not particularly limited in shape, size, arrangement, etc., and is appropriately selected according to the purpose. Although it is possible, it is preferable to partially pattern the surface of the capsule endoscope. Such a capsule endoscope can be manufactured as follows.

-Manufacturing method of capsule endoscope-
According to a first aspect of the method for manufacturing a capsule endoscope of the present invention, the surface of the capsule endoscope to which a polymerization initiator has been added is exposed in a pattern, the fluorine-containing compound is reacted at the exposed portion, and the capsule endoscope A graft chain containing fluorine atoms is formed in a pattern on the surface of the endoscope.
In the second embodiment of the method for producing a capsule endoscope of the present invention, the surface of the capsule endoscope to which the polymerization initiator has been added is exposed in a pattern, and the phosphorylcholine group-containing compound is reacted at the exposed portion, A graft chain containing a phosphorylcholine group is formed in a pattern on the surface of the capsule endoscope.

Specifically, the method for producing a capsule endoscope of the present invention includes (1) a step of immobilizing a polymerization initiator on the surface of the capsule endoscope, and (2) a fluorine-containing compound or phosphorylcholine from the immobilized polymerization initiator. The group-containing compound is preferably prepared through a step of starting graft polymerization and generating a graft chain having a perfluoro group or a phosphorylcholine group.
In the step (2), by performing patterning using a mask or the like, graft chains can be formed in a pattern on the surface of the capsule endoscope.

<(1) Step of immobilizing a polymerization initiator on the surface of the capsule endoscope>
The step of fixing the polymerization initiator on the capsule endoscope surface is not particularly limited and may be appropriately selected depending on the intended purpose. From the viewpoint of ease of operation and large area applicability, A method in which an initiator having a binding end group such as an agent is attached to the surface of the capsule endoscope, preferably over the entire desired region is preferable. There is no restriction | limiting in particular as this adhesion method, According to the objective, it can select suitably, For example, the apply | coating method, the spray method, the immersion method, etc. are mentioned.

-Polymerization initiator-
The polymerization initiator is not particularly limited and may be appropriately selected depending on the intended purpose. However, the polymerization initiator is bonded to the substrate and a portion that initiates atom transfer radical polymerization (hereinafter sometimes referred to as “starting site”). Any known compound can be used as long as it has a possible moiety (binding site) in the same molecule.

In general, it is preferable to introduce an organic halide (for example, an ester compound having a halogen at the α-position or a compound having a halogen at the benzyl position) or a sulfonyl halide compound as a partial structure as the initiation site. Further, as long as it has a function as a similar polymerization initiator, a compound having a group replacing a halogen, for example, a diazonium group, an azide group, an azo group, a sulfonium group, an oxonium group, or the like may be used. .
Specific examples of the compound that can be introduced as the initiation site include compounds exemplified below.

C ₆ H ₅ -CH ₂ X,
_{C 6 H 5 -C (H)} (X) CH 3, or _{C 6 H 5 -C (X)} (CH 3) 2
However, in each structural formula, C ₆ H ₅ represents a phenyl group. X represents a chlorine atom, a bromine atom, or an iodine atom.

R ¹ —C (H) (X) —CO ₂ R ² ,
R ¹ —C (CH ₃ ) (X) —CO ₂ R ² ,
^{R 1 -C (H) (X} ) -C (O) R 2, or _{^{R 1 -C (CH 3) (}} X) -C (O) R 2
However, in each structural formula, R ¹ and R ² may be the same as or different from each other, and are a hydrogen atom, an alkyl group having 1 to 20 carbon atoms, or an aryl group having 6 to 20 carbon atoms. Or an aralkyl group having 7 to 20 carbon atoms. X represents a chlorine atom, a bromine atom, or an iodine atom.

R ¹ —C ₆ H ₄ —SO ₂ X
However, in said structural formula, R < ¹ > and X are synonymous with what was mentioned above.

The initiation site of the initiator is an α-halogen ester compound from the viewpoint of stability over time.
Examples of the binding site present in the initiator, that is, the substrate binding group (functional group capable of binding to the substrate) include, for example, thiol group, disulfide group, alkenyl group, crosslinkable silyl group, hydroxyl group, epoxy group, amino group. Group, amide group, and the like. Among these, a thiol group and a crosslinkable silyl group are particularly preferable as the substrate binding group.

Specific examples of the initiator having the initiation site and the binding site, that is, the initiator having a substrate binding group introduced into the partial structure having the initiation ability, include, for example, the structure represented by the following structural formula (8). What has is illustrated.
^{R 4 R 5 C (X)} -R 6 -R 7 -C (H) (R 3) CH 2 -
_{^{- [Si (R 9) 2}} -b (Y) b O] m -Si (R 10) 3-a (Y) a ··· structural formula (8)
In the Structural Formula ^{(8), R 3, R} 4, R 5, R 6, and ^{R 7} have the same meanings as ^{R 1} and ^{R 2.}
X has the same meaning as X described above.
R ⁹ and R ¹⁰ are all alkyl groups having 1 to 20 carbon atoms, aryl groups, aralkyl groups, or (R ′) ₃ SiO— (wherein R ′ is a monovalent hydrocarbon having 1 to 20 carbon atoms) The three R ′ groups may be the same or different), and when two or more R ⁹ or R ¹⁰ are present, they are the same May be different.
Y represents a hydroxyl group, a halogen atom, or a hydrolyzable group, and when two or more Y are present, they may be the same or different.
a represents 0, 1, 2, or 3; b represents 0, 1, or 2. m is an integer of 0-19. However, it shall be satisfied that a + mb ≧ 1.

Examples of the compound represented by the structural formula (8) are shown below.
_{XCH 2 C (O) O (} CH 2) nSi (OCH 3) 3,
_{CH 3 C (H) (X} ) C (O) O (CH 2) n Si (OCH 3) 3,
(CH ₃ ) ₂ C (X) C (O) O (CH ₂ ) _n Si (OCH ₃ ) ₃ ,
(CH ₃ ) ₂ C (X) C (O) O (CH ₂ ) _n SiCl ₃ ,
XCH ₂ C (O) O (CH ₂ ) nSiCl ₃ ,
_{CH 3 C (H) (X} ) C (O) O (CH 2) n Si (CH 3) (OCH 3) 2, or _{(CH 3) 2 C (X} ) C (O) O (CH 2) n SiCl ₃ ,
However, in said each structural formula, X represents a chlorine atom, a bromine atom, or an iodine atom. n represents an integer of 0 to 20.

Next, other specific examples of the initiator having the initiation site and the binding site include those having a structure represented by the following structural formula (9).
^{_{(R 10) 3-a (}} Y) a Si- [OSi (R 9) 2-b (Y) b] m -
—CH ₂ —C (H) (R ³ ) —R ¹¹ —C (R ⁴ ) (X) —R ⁸ —R ⁵ ... Structural formula (9)
However, in said structural formula (9), R < ³ >, R < ⁴ >, R < ⁵ >, R < ⁷ >, R < ⁸ >, R <^9> , R < ¹⁰ >, a, b, m, X, and Y are as defined above.

Examples of the compound represented by the structural formula (9) are shown below.
_{(CH 3 O) 3 SiCH 2} CH 2 C (H) (X) C 6 H 5,
C1 ₃ SiCH ₂ CH ₂ C (H) (X) C ₆ H ₅ ,
C1 ₃ Si (CH ₂ ) ₂ C (H) (X) —CO ₂ R,
_{(CH 3 O) 2 (CH} 3) Si (CH 2) 2 C (H) (X) -CO 2 R,
_{(CH 3 O) 3 Si (} CH 2) 3 C (H) (X) -CO 2 R,
_{(CH 3 O) 2 (CH} 3) Si (CH 2) 3 C (H) (X) -CO 2 R,
However, in said each structural formula, X represents a chlorine atom, a bromine atom, or an iodine atom, R represents a C1-C20 alkyl group, an aryl group, or an aralkyl group.

-Graft polymerization method-
As a method for generating a graft polymer on the surface of the polymerization initiator layer, a means generally called surface graft polymerization is used. The graft polymerization means a method of synthesizing a graft (grafting) polymer by giving an active species on a polymer compound chain, thereby further bonding and polymerizing another monomer for initiating polymerization, When the polymer compound that gives the active species forms a solid surface, it is called surface graft polymerization. The graft polymer produced in the present invention includes those obtained by bonding a desired polymer to an active species on a polymer compound chain. In the present invention, the polymer compound to which the active species is given is a polymer compound that constitutes the above-described immobilized polymerization initiation layer.

  In the present invention, the graft polymerization is performed by treating the surface of the capsule endoscope on the entire surface or an image-like polymerization initiator layer with plasma or electron beam, generating radicals on the surface, and starting polymerization. Then, a graft polymer is produced by reacting the active surface with a fluorine-containing compound or a phosphorylcholine group-containing compound.

-Application of energy to give active species to the polymerization initiator layer-
The energy application method for imparting active species to the polymerization initiator layer is not particularly limited as long as it is a method capable of applying energy capable of decomposing the polymerization initiator in the polymerization initiator layer, and is appropriately selected according to the purpose. For example, actinic ray irradiation such as exposure is preferable from the viewpoint of cost and simplicity of the apparatus.
Examples of the actinic rays that can be used for the energy application include ultraviolet rays, visible light, and infrared light. Among these actinic rays, ultraviolet rays and visible light are preferable, and ultraviolet rays are preferable from the viewpoint of excellent polymerization rate. Particularly preferred. Moreover, it is preferable that the main wavelength of actinic rays is 250 nm or more and 800 nm or less.
Examples of the light source include a low-pressure mercury lamp, a high-pressure mercury lamp, a fluorescent lamp, a xenon lamp, a carbon arc lamp, a tungsten incandescent lamp, and sunlight.
The time required for irradiation with the actinic ray is not particularly limited and may be appropriately selected depending on the purpose. Usually, several seconds to 24 hours are preferable.

In order to produce the graft polymer using the graft polymerization, the surface of the capsule endoscope provided with the polymerization initiation layer is immersed in a solution containing a fluorine-containing compound or a phosphorylcholine group-containing compound, and then light irradiation is performed. A method is used in which active species are generated on the surface of the polymerization initiator layer, and the compound is graft-polymerized to the active species.
As the fluorine-containing compound or phosphorylcholine group-containing compound, those described above can be used.

The graft polymerization reaction may be carried out without a solvent, that is, without using a solvent alone, or may be carried out in various solvents. Examples of the solvent that can be used in the polymerization reaction include hydrocarbon solvents such as benzene and toluene; ether solvents such as diethyl ether, tetrahydrofuran, diphenyl ether, anisole, and dimethoxybenzene; halogenated carbonization such as methylene chloride, chloroform, and chlorobenzene. Hydrogen solvents; ketone solvents such as acetone, methyl ethyl ketone, methyl isobutyl ketone; alcohol solvents such as methyl alcohol, ethyl alcohol, n-propyl alcohol, isopropyl alcohol, n-butyl alcohol, t-butyl alcohol; acetonitrile, propio Nitrile solvents such as nitrile and benzonitrile; ester solvents such as ethyl acetate and butyl acetate; carbonate solvents such as ethylene carbonate and propylene carbonate; water, etc. It is below. These can be used individually by 1 type or in mixture of 2 or more types.
In the graft polymerization reaction using the solvent, generally, a capsule endoscope in which a monomer is added to a solvent, a catalyst is added as necessary, and an initiator is fixed in the solvent is then used. It is performed by dipping and reacting for a predetermined time. On the other hand, the graft polymerization reaction without solvent is generally performed at room temperature or in a heated state up to 100 ° C.

The capsule endoscope manufactured as described above has a graft chain formed in a pattern on the surface thereof, and a medicinal component is bonded to the graft chain. Examples of the bonding method include ionic bonding and covalent bonding as described above, and among these, ionic bonding is particularly preferable. As the ionic bond, for example, a capsule endoscope having a graft chain containing a basic group is immersed in an aqueous solution in which penicillin G having an acidic group is dissolved, and penicillin G as a medicinal component is bound to the graft chain. Can be made.
Moreover, the capsule endoscope which has the graft chain containing an acidic group can be immersed in the aqueous solution which melt | dissolved the streptomycin which has a basic group, and streptomycin as a medicinal component can be combined with a graft chain.

  In the capsule endoscope of the present invention, the graft chain is formed in a pattern on the surface thereof, and there are portions having different friction coefficients on the capsule surface, so that the capsule is held, rotated, etc. with a part as a fulcrum It is also possible to control the movement.

  Examples of the present invention will be described below, but the present invention is not limited to the following examples.

Example 1
-Formation of polymerization initiation layer-
The casing surface (material: polyethylene) of a capsule endoscope (outer diameter 11 mm, total length 26 mm) as shown in FIGS. 1 and 2 was subjected to plasma discharge treatment (manufactured by KEYENCE, ST-7000).
Next, the capsule endoscope was prepared using a silane coupling agent (5-trichlorosilylpentyl) -2-bromo-2-methylpropio prepared by the method described in Macromolecules, 32, 1424, (1999). It was immersed in a 1% by weight dehydrated toluene solution of nate overnight.
Next, the capsule endoscope was taken out, washed sequentially with toluene and methanol, and a capsule endoscope in which a silane coupling agent having a binding end group as a polymerization initiator was fixed on the surface was prepared.

-Pattern exposure and development-
The polymerization initiator layer of the obtained capsule endoscope was irradiated with UV at an irradiation energy of 300 mJ / cm ² using a high-pressure mercury lamp through a pattern film for 15 minutes. As a result, the polymerization initiator in the exposed area was deactivated.

-Graft polymerization-
A capsule endoscope in which a patterned polymerization initiator layer is formed is prepared by mixing 30 g of acrylic acid (manufactured by Wako Pure Chemical Industries, Ltd.) and 70 g of propylene glycol monomethyl ether (manufactured by Wako Pure Chemical Industries, Ltd.). It was immersed in a uniform solution and irradiated for 30 minutes at 300 mJ / cm ² using a high-pressure mercury lamp. After light irradiation, it was thoroughly washed with ion exchange water. As described above, a capsule endoscope having a graft polymer obtained by graft polymerization of an acrylic acid monomer on the surface of the polymerization initiator layer was obtained.

-Loading of drug-
The capsule endoscope having the graft chain was immersed in a solution obtained by dissolving 0.1 g of streptomycin in 100 g of purified water for 12 hours. Subsequently, it was washed with water and dried to produce a capsule endoscope having streptomycin on the surface.

(Example 2)
In Example 1, a capsule endoscope having a graft polymer in a pattern on the surface of the polymerization initiator layer was produced using 2-methacryloyloxyethyldimethylethylammonium instead of acrylic acid.
Next, the capsule endoscope having the graft chain was immersed in a solution obtained by dissolving 0.1 g of penicillin G in 100 g of purified water for 12 hours. Next, it was washed with water and dried to produce a capsule endoscope having penicillin G on the surface.

(Example 3)
In Example 1, 30 g of acrylic acid (manufactured by Wako Pure Chemical Industries, Ltd.) and 70 g of propylene glycol monomethyl ether (manufactured by Wako Pure Chemical Industries, Ltd.), CH ₂ = CHCOOCH ₂ CH ₂ Rf (where Rf is represents _{-C n F 2n + 1 -CF 3} , n = is 8) (FAMAC, and Daikin Fine Chemical Laboratory Ltd.) 7 g, and 2-methacryloyloxy oxyethyl dimethyl ethyl ammonium 3g, propylene glycol monomethyl ether (manufactured by Wako Pure Chemical Industries, A capsule endoscope having a graft polymer in a pattern on the surface of the polymerization initiator layer was produced in the same manner as in Example 1 except that 90 g was used.
Next, the capsule endoscope having the graft chain was immersed in a solution obtained by dissolving 0.1 g of penicillin G in 100 g of purified water for 12 hours. Next, it was washed with water and dried to produce a capsule endoscope having penicillin G on the surface.

Example 4
In Example 1, 30 g of acrylic acid (manufactured by Wako Pure Chemical Industries, Ltd.) and 70 g of propylene glycol monomethyl ether (manufactured by Wako Pure Chemical Industries, Ltd.), 5 g of 2-methacryloyloxyethyl phosphoric choline, 2- A graft polymer was patterned on the surface of the polymerization initiator layer in the same manner as in Example 1 except that 5 g of methacryloyloxyethyldimethylethylammonium and 90 g of propylene glycol monomethyl ether (Wako Pure Chemical Industries, Ltd.) were used. A capsule endoscope was prepared.
Next, the capsule endoscope having the graft chain was immersed in a solution obtained by dissolving 0.1 g of penicillin G in 100 g of purified water for 12 hours. Next, it was washed with water and dried to produce a capsule endoscope having penicillin G on the surface.

(Comparative Example 1)
In Example 1, a capsule endoscope of Comparative Example 1 was obtained in the same manner as in Example 1 except that no graft chain was provided on the surface of the capsule endoscope and no medicinal component was supported.

  Next, for each of the capsule endoscopes of Examples 1 to 4 and Comparative Example 1, the residence time, antibacterial properties, and protein adsorption amount in the vinyl tube were measured as follows. The results are shown in Table 1.

<Measurement of residence time in vinyl pipe>
A rigid vinyl chloride tube having a nominal diameter of 25 mm and a total length of 30 cm was used. One end of the vinyl tube was lifted 5 cm above the other end, and 100 ml of water was allowed to flow from the upper end in one minute. And each capsule endoscope of the comparative example 1 was inserted, and the residence time until this capsule endoscope was discharged | emitted out of a vinyl tube was measured.

<Measurement of protein adsorption amount>
Each capsule endoscope of Examples 1-2 and Comparative Example 1 was immersed at 37 ° C. for 1 day in a protein solution in which 10 g of dried egg white was dissolved in 100 g of physiological saline. Subsequently, after rinsing with physiological saline, it was immersed in 100 ml of a 1% by weight sodium dodecyl sulfate aqueous solution, the protein was peeled off from the capsule endoscope, and the aqueous solution was dried to be dissolved in this aqueous solution. Protein was quantified. Subtraction was performed assuming that 1 g of sodium dodecyl sulfate was contained.

<Evaluation of antibacterial properties>
After applying 5 mass% sugar water on the surface of each capsule endoscope of Examples 1 to 4 and Comparative Example 1, it was left in the room for 4 days, and the presence or absence of colonies was visually determined based on the following criteria.
〔Evaluation criteria〕
○: No colony generated ×: Colony generated

  The capsule endoscope of the present invention has a medicinal component on at least a part of its surface, can be effectively treated and examined at a target site in a living body, has excellent anti-contamination properties such as blood and protein, and has a posture. Control, movement control, and position control are easy, and it is suitably used as a capsule endoscope that is safe and useful.

FIG. 1 is an enlarged vertical cross-sectional view showing an outline of an example of a configuration inside a casing of a capsule endoscope of the present invention. FIG. 2 is a front view of the capsule endoscope of FIG. 1 viewed from the front.

Explanation of symbols

DESCRIPTION OF SYMBOLS 1 Lens barrel 1a Objective lens 2 Light source 3 Electronic control component 4 Image pick-up element 5 Element frame 6 Peripheral circuit board 7 Flexible board 8 Power supply 10 Case 100 Capsule endoscope

Claims (10)

  A capsule endoscope having a medicinal component on at least a part of the surface of the capsule endoscope.   The medicinal ingredients are peripheral nerve agent, central nervous agent, hormone agent, otacoid, cardiovascular agent, respiratory agent, digestive agent, urogenital agent, skin agent, vitamin, The capsule endoscope according to claim 1, wherein the capsule endoscope is at least one selected from a chemotherapeutic agent, a disinfectant, an antiseptic, a biological preparation, and a traditional Chinese medicine.   The capsule endoscope according to any one of claims 1 to 2, wherein the capsule endoscope has a medicinal component through a graft chain provided on a surface of the capsule endoscope.   The capsule endoscope according to claim 3, wherein the medicinal component is bound to the graft chain by an ionic bond.   The capsule endoscope according to any one of claims 1 to 4, wherein the medicinal component is detachable from the graft chain at a target site in the living body.   The capsule endoscope according to any one of claims 3 to 5, wherein the graft chains are formed in a pattern on the surface of the capsule endoscope.   The capsule endoscope according to any one of claims 3 to 6, wherein the graft chain is obtained by polymerizing at least a fluorine-containing compound.   The capsule endoscope according to claim 7, wherein the fluorine-containing compound has a polymerizable group.   The capsule endoscope according to any one of claims 3 to 6, wherein the graft chain is obtained by polymerizing at least a phosphorylcholine group-containing compound. The capsule endoscope according to claim 9, wherein the phosphorylcholine group-containing compound has a polymerizable group.

Images